Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14997367 | 0.81 | TDP1 (0.37) | TDP1PIK3CDLOXLOXL3LOXL2 | |
| SCHEMBL27030233 | 0.81 | LOX (0.41) | TDP1PIK3CDLOXLOXL3LOXL2 | |
| SCHEMBL29829879 | 0.81 | LOX (0.41) | TDP1PIK3CDLOXLOXL3LOXL2 | |
| Hydrochloric Acid SCHEMBL27030986 | 0.79 | AOC1 (0.39) | TDP1PIK3CDLOXLOXL3LOXL2 | |
| SCHEMBL27635268 | 0.79 | TDP1 (0.35) | TDP1PIK3CDLOXLOXL3LOXL2 | |
| SCHEMBL18398211 | 0.79 | NOS3 (0.47) | TDP1NOS3NOS1NOS2 | |
| SCHEMBL5373562 | 0.79 | PDXK (0.41) | TDP1PIK3CDLOXLOXL3LOXL2 | |
| SCHEMBL31206394 | 0.79 | PDXK (0.41) | TDP1PIK3CDLOXLOXL3LOXL2 | |
| SCHEMBL15965801 | 0.75 | — | — | |
| SCHEMBL27635364 | 0.73 | NOS2 (0.42) | TDP1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219463-B1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| US-20240166627-A1 | Terpyridinedione compound or salt thereof, and preparation method and application thereof | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-23 | — | — | US | disclosed |
| CN-116648244-B | Terpyridyl dione compound or salt thereof, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-116648244-A | Terpyridyl dione compound or salt thereof, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-4219463-A1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219463-A1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023016535-A1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016535-A1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166627-A1 | Terpyridinedione compound or salt thereof, and preparation method and application thereof | TNF, MAPKAPK2, MAPK1 | TDP1 2835/4885PIK3CD 1174/4885LOX 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.